Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

Inclusion Criteria:

* Pathologically confirmed advanced (stage IV) non-squamous, non-small cell lung cancer with measurable lesions
* Electronics Coordinating Grop（ECOG）score：0-2
* Expected survival over 3months
* Hemoglobin(HB)≥90 gram(g)/liter(L)；absolute neutrophil count(ANC)≥1.5×109/L；platelet(PLT)≥80×109/L；total-bilirubin（T-BIL）\<1.5 upper limit of normal value（ULN）；alanine aminotransferase（ALT）and aspartate aminotransferase（AST）\<2.5 ULN；Cr≤1.25ULN

Exclusion Criteria:

* Brain metastases, meningococcal meningitis, patients with spinal cord compression with evidence of imaging (computed tomography（CT） / magnetic resonance imaging （MRI）, et cetera（etc.）);
* Uncontrolled hypertension (systolic blood pressure（BP）≥140 millimeter mercury column（mmHg） or diastolic BP ≥90 mmHg, despite optimal drug therapy);
* Hemorrhoid dysfunction (inernational standard ratio(INR)\> 1.5 or prothrombin time (PT)\> ULN + 4 seconds or activated partial thromboplastin(APTT)\> 1.5 ULN) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy;
* Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or the like;
* Patients underwent major surgery or severe traumatic injury, fracture or ulcer in 4 weeks before study;
* Urine routine urine protein ≥ +++, or confirmed 24 hours urinary protein content ≥ 1.0 g;